Shattuck Labs to Present Poster on Gamma Delta T Cell Engager, GADLEN™, Platform at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
AUSTIN, TX and DURHAM, NC, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that preclinical data from its Gamma Delta T Cell Engager, GADLEN™, platform has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020.
Presentation Details
Title: In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells
Date: November 11 – 14, 2020
Time: 9:00 a.m. – 5:00 p.m. EST
Location: Virtual Poster Hall
Abstract Number: 688
Additional meeting information can be found on the SITC website at . The poster presentation will be available under the section of the Company’s website.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit:
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
